Last quarter (Q4 2023), FSD Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, FSD Pharma's net income was $―. See FSD Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Aug 17
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 15.12M	$ 19.23M	$ 27.48M	$ 33.81M	$ 30.60M	$ 19.37K
Operating Income	$ -15.12M	$ -19.23M	$ -27.48M	$ -33.81M	$ -30.60M	$ -19.37K
Net Non Operating Interest Income Expense	$ 35.41K	$ 786.36K	$ 332.94K	-	$ -235.58K	-
Other Income Expense	$ -9.64K	$ -4.77M	$ -521.81K	$ -682.51K	$ 2.38M	-
Pretax Income	$ -15.09M	$ -18.23M	$ -26.59M	$ -33.13M	$ -28.45M	$ -19.37K
Tax Provision	-	-	$ 234.23K	$ 858.48K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -11.55M	$ -17.90M	$ -23.61M	$ -35.29M	$ -31.80M	$ -19.37K
Basic EPS	$ -0.31	$ -0.46	$ -0.61	$ -1.01	$ -2.64	$ >-0.01
Diluted EPS	$ -0.31	$ -0.46	$ -0.61	$ -1.01	$ -2.64	$ >-0.01
Basic Average Shares	$ 76.69M	$ 39.59M	$ 38.73M	$ 34.95M	$ 12.04M	$ 6.57M
Diluted Average Shares	$ 76.69M	$ 39.59M	$ 38.73M	$ 34.95M	$ 12.04M	$ 6.57M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 15.12M	$ 19.23M	$ 27.48M	$ 33.81M	$ 30.60M	$ 19.37K
Net Income From Continuing And Discontinued Operation	$ -11.55M	$ -17.90M	$ -23.61M	$ -35.29M	$ -31.80M	$ -19.37K
Normalized Income	$ -15.05M	-	-	-	$ -30.83M	$ -19.37K
Interest Expense	$ 32.30K	-	-	-	$ 235.58K	-
EBIT	$ -15.06M	-	$ -27.11M	$ -33.13M	$ -28.22M	$ -19.37K
EBITDA	$ -12.78M	-	$ -22.57M	$ -29.09M	$ -24.32M	$ -19.37K

Currency in USD

FSD Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing